600
Participants
Start Date
December 6, 2019
Primary Completion Date
July 12, 2021
Study Completion Date
July 12, 2021
V116
Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
Pneumovax™23
Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Meridian Clinical Research, LLC ( Site 0025), Endwell
Rochester Clinical Research, Inc. ( Site 0002), Rochester
Indago Research & Health Center, Inc ( Site 0011), Hialeah
Research Centers of America, LLC ( Site 0001), Hollywood
Clinical Research of South Florida ( Site 0008), Coral Gables
QPS Miami Research Associates ( Site 0016), Miami
L&C Professional Medical Research Institute ( Site 0009), Miami
Advanced Medical Research Institute ( Site 0010), Miami
Simon Williamson Clinic ( Site 0004), Birmingham
Advanced Medical Research ( Site 0017), Maumee
PriMED Clinical Research ( Site 0021), Dayton
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0018), Troy
Optimal Research ( Site 0006), Peoria
Meridian Clinical Research, LLC ( Site 0024), Norfolk
Benchmark Research ( Site 0012), Metairie
Diagnostics Research Group ( Site 0013), San Antonio
Advanced Clinical Research ( Site 0022), West Jordan
Central Arizona Medical Associates ( Site 0003), Mesa
Wake Research Clinical Research Center of Nevada, LLC ( Site 0014), Las Vegas
Kaiser Permanente Center for Health Research ( Site 0015), Portland
Merck Sharp & Dohme LLC
INDUSTRY